Accelerate Diagnostics (AXDX) Earns News Sentiment Score of 0.13
Media coverage about Accelerate Diagnostics (NASDAQ:AXDX) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Accelerate Diagnostics earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 47.7644445130488 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s analysis:
- Fluctuating Three Stocks: Accelerate Diagnostics, Inc. (NASDAQ:AXDX), The Navigators Group, Inc. (NASDAQ:NAVG … (thestreetpoint.com)
- Shares Under the Microscope: Accelerate Diagnostics, Inc. (NasdaqCM:AXDX) Ratio & Valuation Review (baycityobserver.com)
- Accelerate Diagnostics Inc (AXDX) Expected to Post Quarterly Sales of $2.89 Million (americanbankingnews.com)
- Accelerate Diagnostics Inc (AXDX) Expected to Post Earnings of -$0.44 Per Share (americanbankingnews.com)
- Accelerate Diagnostics Inc (AXDX) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
Accelerate Diagnostics stock traded up $0.15 during mid-day trading on Friday, hitting $23.75. The company had a trading volume of 777 shares, compared to its average volume of 165,796. The company has a current ratio of 27.12, a quick ratio of 25.67 and a debt-to-equity ratio of 1.22. Accelerate Diagnostics has a 12-month low of $16.75 and a 12-month high of $30.35. The firm has a market cap of $1.27 billion, a PE ratio of -20.43 and a beta of 2.20.
A number of equities research analysts recently commented on the company. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Thursday, August 9th. BidaskClub upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, May 18th. Piper Jaffray Companies restated a “buy” rating and issued a $24.00 price objective on shares of Accelerate Diagnostics in a research report on Tuesday, August 7th. ValuEngine upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Monday, June 11th. Finally, Craig Hallum started coverage on Accelerate Diagnostics in a research report on Thursday, May 24th. They issued a “hold” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $24.50.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Further Reading: NASDAQ Stock Market Explained
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.